UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 61 filers reported holding UNIQURE NV in Q4 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,011,000 | +24.7% | 30,000 | +66.7% | 0.89% | -2.9% |
Q2 2020 | $811,000 | -65.8% | 18,000 | -64.0% | 0.92% | -71.3% |
Q1 2020 | $2,373,000 | -17.2% | 50,000 | +25.0% | 3.19% | +4.5% |
Q4 2019 | $2,866,000 | +40.0% | 40,000 | -23.1% | 3.06% | +19.7% |
Q3 2019 | $2,047,000 | -49.6% | 52,000 | 0.0% | 2.55% | -41.9% |
Q2 2019 | $4,064,000 | +23.9% | 52,000 | -5.5% | 4.40% | +35.4% |
Q1 2019 | $3,281,000 | +107.0% | 55,000 | 0.0% | 3.25% | +63.3% |
Q4 2018 | $1,585,000 | +8.9% | 55,000 | +37.5% | 1.99% | +28.6% |
Q3 2018 | $1,456,000 | +10.1% | 40,000 | +14.3% | 1.55% | +15.6% |
Q2 2018 | $1,323,000 | +25.0% | 35,000 | -22.2% | 1.34% | +5.2% |
Q1 2018 | $1,058,000 | -32.5% | 45,000 | -43.8% | 1.27% | -35.5% |
Q4 2017 | $1,567,000 | +55.5% | 80,000 | -23.8% | 1.97% | +86.5% |
Q3 2017 | $1,008,000 | +30.2% | 105,000 | -16.0% | 1.06% | +36.2% |
Q2 2017 | $774,000 | -10.7% | 125,000 | -16.7% | 0.78% | -11.4% |
Q1 2017 | $867,000 | – | 150,000 | – | 0.88% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |